On February 27, 2019 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, reported that preclinical data highlighting the potential of CB-708, the company’s orally bioavailable CD73 inhibitor will be presented in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019, taking place March 29 to April 3, 2019 in Atlanta, Georgia (Press release, Calithera Biosciences, FEB 27, 2019, View Source [SID1234535228]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the presentation are as follows:
Title: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73 Presenter:Clarissa Lee, Calithera Biosciences Session
Title: Novel Immunomodulatory Agents 2, Abstract #4134
Session Date and Time: Tuesday April 2, 20191:00 p.m. ET-5:00 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25, Board 8
Additional meeting information can be found at the AACR (Free AACR Whitepaper) website www.aacr.org.
The poster presentation will be available at www.calithera.com in the Publications Section.
CD73 is an enzyme in the tumor microenvironment that produces adenosine, a powerful inhibitor of immune function in tumors. CD73 is expressed across a wide range of tumor types and tumor infiltrating leukocytes. Expression of CD73 often correlates with poor prognosis in patients with cancer. Blockade of adenosine production by CD73 inhibition is expected to reverse immunosuppression in the tumor microenvironment and enhance the immune system’s ability to fight the cancer. CB-708 is an orally bioavailable small molecule inhibitor of CD73.